Cyclic RGD Peptide Targeting Coated Nano Drug Co-Delivery System for Therapeutic Use in Age-Related Macular Degeneration Disease

Autor: Fei Xu, Ge Li, Lifu Luo, Jiaxin Liu, Lesheng Teng, Fengying Sun, Youxin Li, Jicong Chen
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Vascular Endothelial Growth Factor A
genetic structures
Polymers
Pharmaceutical Science
retinal pigment epithelial cells
Pharmacology
Umbilical vein
Dexamethasone
Analytical Chemistry
Pathogenesis
chemistry.chemical_compound
Macular Degeneration
0302 clinical medicine
Drug Discovery
Fluorescein
0303 health sciences
Drug Carriers
vascular endothelial growth factor
anti-angiogenic drug
Vascular endothelial growth factor
Bevacizumab
Choroidal neovascularization
Chemistry (miscellaneous)
Molecular Medicine
medicine.symptom
medicine.drug
Adult
Peptides
Cyclic
Article
Retina
Cell Line
lcsh:QD241-441
03 medical and health sciences
lcsh:Organic chemistry
medicine
Humans
Physical and Theoretical Chemistry
age-related macular degeneration
030304 developmental biology
Organic Chemistry
Biological Transport
Epithelial Cells
Macular degeneration
medicine.disease
eye diseases
chemistry
030221 ophthalmology & optometry
Nanoparticles
sense organs
Zdroj: Molecules
Volume 25
Issue 21
Molecules, Vol 25, Iss 4897, p 4897 (2020)
ISSN: 1420-3049
Popis: Vascular endothelial growth factor (VEGF) expression increased significantly in the pathogenesis of age-related macular degeneration, which induced the formation of pathological blood vessels. Dexamethasone is an exogenous anti-angiogenic drug while bevacizumab is an endogenous anti-angiogenic drug. They both have been widely used in ophthalmology. However, independent administration is not enough to completely block the development of choroidal neovascularization (CNV), and the number of eyes vitreous injections is limited. Reasonable combination of drugs may produce significantly better therapeutic effect than single drug treatment. The cyclic RGD (cRGD) peptide has a particularly high affinity with retinal pigment epithelial cells, where VEGF secretes from. In this study, we prepared nanoparticles of bevacizumab and dexamethasone with cRGD peptide as the target (aBev/cRGD-DPPNs). The particle size of the aBev/cRGD-DPPNs was 213.8 ±
1.5 nm, SEM results showed that the nano-carriers were well dispersed and spherical. The cell uptake study demonstrated the selectivity of the aBev/cRGD-DPPN to ARPE-19 with &alpha
V&beta
3 over expressed. The aBev/cRGD-DPPNs had a better apoptosis induction effect and an obvious inhibitory effect on migration, invasion, and capillary-like structures formation of human umbilical vein epithelial cells. The fluorescein fundus angiography study, immunohistochemistry and histopathological evaluation showed the aBev/cRGD-DPPNs greatly reduced the development of CNV on a rabbit model.
Databáze: OpenAIRE
Externí odkaz: